Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;14(1):10-3.
Epub 2012 Jan 1.

Serum level of matrix metalloproteinase-3 in patients with oral lichen planus

Affiliations

Serum level of matrix metalloproteinase-3 in patients with oral lichen planus

M Farzin et al. Iran Red Crescent Med J. 2012 Jan.

Abstract

Background: Oral Lichen planus (OLP) is a chronic lesion of the oral mucosa with unknown origin. Basement membrane changes are common in OLP and may be mediated by proteases such as matrix metalloproteinase (MMPs) and mast cell chymase. The aim of our study was to evaluate the level of serum MMP-3 in OLP com-pared to normal individuals and assess its clinical significance.

Methods: Thirty four serum samples from patients diagnosed with OLP (12 males, 22 females, age: 42.2±10.8 years) and 34 serum samples from healthy control subjects (11 males, 23 females, age: 42.5±13.3 years) were collected and MMP-3 concentration was measured by ELISA.

Results: The serum MMP-3 level in OLP patients was higher (21.64±24.31 ng/ml) compared with healthy con-trols (16.52±23.63 ng/ml), but showed no statistically significant difference. A statistically significant difference was demonstrated between the two types of OLP, being more pronounced in the erosive/atrophic form 6).

Conclusion: The different clinical appearances of OLP are associated with significant differences in MMP-3 serum level.

Keywords: Lichen planus; Matrix metalloproteinase-3; Oral.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Similar articles

Cited by

References

    1. Ghabanchi J, Fattahi MJ, Mardani M, Tadbir AA, Paydar AA. Polymor­phism of tumor protein P53 codon 72 showed no association with oral li­chen planus in Shiraz, Iran. J Craniofac Surg. 2009;20:2168–70. doi: 10.1097/SC S.0b013e3181bf015e. - DOI - PubMed
    1. Seoane J, Romero MA, Varela-Centelles P, Diz-Dios P, Garcia-Pola MJ. Oral lichen planus: a clinical and morphometric study of oral lesions in relation to clinical presentation. Braz Dent J. 2004;15:9–12. doi: 10.1590/S0103-64 402004000100002. - DOI - PubMed
    1. Gunduz K, Demireli P, Inanir I, Nese N. Expression of matrix metalloproteinases (MMP-2, MMP-3, and MMP-9) and fibronectin in lichen planus. J Cutan Pathol. 2006;33:545–50. doi: 10.1111/j.1600-0560.2006.00456.x. - DOI - PubMed
    1. Ghabanchi J, Bahri Najafi R, Haghnegahdar S. Treatment of oral inflammatory diseases with a new mucoadhesive prednisolone tablet versus triamcinolone acetonide paste. Iran Red Crescent Med J. 2009;11:155–159.
    1. Iraji F, Faghihi G, Asilian A, Siadat AH, Taghavi Larijani F, Akbari M. Comparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: A randomized clinical trial. J Res Med Sci . 2011;16; (Abstract). - PMC - PubMed

LinkOut - more resources